File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation

TitleDonor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation
Authors
Issue Date1999
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 1999, v. 23 n. 11, p. 1201-1203 How to Cite?
AbstractDonor lymphocyte infusion (DLI) has been used successfully to induce remissions in relapse of acute myeloid leukaemia (AML) after bone marrow transplantation (BMT), but molecular eradication of leukaemia has rarely been documented. A patient with AML-M4Eo relapsed after HLA-identical sibling BMT in first complete remission (CR). Cytogenetic and molecular genetic investigations confirmed inv(16) and CBFβ/MYH11 fusion characteristic of M4Eo. A second remission was obtained with chemotherapy. Full donor chimerism was demonstrated by fluorescence in situ hybridisation. However, molecular evidence of minimal residual disease still persisted, and donor lymphocyte infusion (DLI) was administered. This resulted in molecular eradication, and the patient remained in clinical and molecular remission 16 months from DLI. Our observations showed that, for AML relapse after BMT, molecular leukaemia eradication could be achieved by DLI so that, in cases where genetic markers are available, molecular monitoring should be performed to assess the efficacy of treatment.
Persistent Identifierhttp://hdl.handle.net/10722/162323
ISSN
2015 Impact Factor: 3.636
2015 SCImago Journal Rankings: 1.585
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLee, CKen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:18:58Z-
dc.date.available2012-09-05T05:18:58Z-
dc.date.issued1999en_US
dc.identifier.citationBone Marrow Transplantation, 1999, v. 23 n. 11, p. 1201-1203en_US
dc.identifier.issn0268-3369en_US
dc.identifier.urihttp://hdl.handle.net/10722/162323-
dc.description.abstractDonor lymphocyte infusion (DLI) has been used successfully to induce remissions in relapse of acute myeloid leukaemia (AML) after bone marrow transplantation (BMT), but molecular eradication of leukaemia has rarely been documented. A patient with AML-M4Eo relapsed after HLA-identical sibling BMT in first complete remission (CR). Cytogenetic and molecular genetic investigations confirmed inv(16) and CBFβ/MYH11 fusion characteristic of M4Eo. A second remission was obtained with chemotherapy. Full donor chimerism was demonstrated by fluorescence in situ hybridisation. However, molecular evidence of minimal residual disease still persisted, and donor lymphocyte infusion (DLI) was administered. This resulted in molecular eradication, and the patient remained in clinical and molecular remission 16 months from DLI. Our observations showed that, for AML relapse after BMT, molecular leukaemia eradication could be achieved by DLI so that, in cases where genetic markers are available, molecular monitoring should be performed to assess the efficacy of treatment.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.subject.meshAdulten_US
dc.subject.meshBone Marrow Transplantationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIn Situ Hybridization, Fluorescenceen_US
dc.subject.meshLeukemia, Myeloid, Acute - Therapyen_US
dc.subject.meshLymphocyte Transfusionen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshTissue Donorsen_US
dc.subject.meshTransplantation, Homologousen_US
dc.titleDonor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantationen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1038/sj.bmt.1701771-
dc.identifier.pmid10382962-
dc.identifier.scopuseid_2-s2.0-0032972810en_US
dc.identifier.hkuros41979-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032972810&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue11en_US
dc.identifier.spage1201en_US
dc.identifier.epage1203en_US
dc.identifier.isiWOS:000080621100016-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLee, CK=7410162028en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats